$158.00
0.040.03%
At Close: -
$158.00
00.00%
After Hours: 4:45 PM EDT
15 minutes delayed
Sarepta Therapeutics
SRPTNASDAQ
Sarepta Therapeutics (NASDAQ:SRPT) Stock, Analyst Ratings, Price Targets, Predictions
Sarepta Therapeutics Inc has a consensus price target of $184.48, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from Needham, Citigroup, and Morgan Stanley on June 27, 2024, June 26, 2024, and June 24, 2024. With an average price target of $203.67 between Needham, Citigroup, and Morgan Stanley, there's an implied 28.90% upside for Sarepta Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
Citigroup
Morgan Stanley
Evercore ISI Group
BMO Capital
1calculated from analyst ratings
Analyst Ratings for Sarepta Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/27/2024 | Buy Now | 48.73% | Needham | Gil Blum | — | Reiterates | Buy → Buy | Get Alert |
| 06/26/2024 | Buy Now | 11.39% | Citigroup | David Hoang | $172 → $176 | Downgrade | Buy → Neutral | Get Alert |
| 06/24/2024 | Buy Now | 26.58% | Morgan Stanley | Matthew Harrison | $165 → $200 | Maintains | Overweight | Get Alert |
| 06/24/2024 | Buy Now | 17.09% | Evercore ISI Group | Gavin Clark-Gartner | $139 → $185 | Maintains | In-Line | Get Alert |
| 06/24/2024 | Buy Now | 26.58% | BMO Capital | Kostas Biliouris | $170 → $200 | Maintains | Outperform | Get Alert |
| 06/24/2024 | Buy Now | 45.57% | Leerink Partners | Mani Foroohar | $165 → $230 | Maintains | Outperform | Get Alert |
| 06/21/2024 | Buy Now | 4.43% | Morgan Stanley | Matthew Harrison | $165 → $165 | Reiterates | Overweight → Overweight | Get Alert |
| 06/21/2024 | Buy Now | -0.63% | Piper Sandler | Biren Amin | $157 → $157 | Maintains | Overweight | Get Alert |
| 06/21/2024 | Buy Now | -18.99% | Cantor Fitzgerald | Kristen Kluska | $128 → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 06/21/2024 | Buy Now | 15.19% | RBC Capital | Brian Abrahams | $142 → $182 | Maintains | Sector Perform | Get Alert |
| 06/21/2024 | Buy Now | 43.04% | Barclays | Gena Wang | $185 → $226 | Maintains | Overweight | Get Alert |
| 06/21/2024 | Buy Now | 26.58% | Baird | Brian Skorney | $170 → $200 | Maintains | Outperform | Get Alert |
| 06/21/2024 | Buy Now | 34.81% | B of A Securities | Tazeen Ahmad | $166 → $213 | Maintains | Buy | Get Alert |
| 06/21/2024 | Buy Now | 48.73% | Needham | Gil Blum | $166 → $235 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | 7.59% | BMO Capital | Kostas Biliouris | $170 → $170 | Maintains | Outperform | Get Alert |
| 06/14/2024 | Buy Now | 7.59% | BMO Capital | Kostas Biliouris | $170 → $170 | Maintains | Outperform | Get Alert |
| 05/31/2024 | Buy Now | -0.63% | Piper Sandler | Biren Amin | → $157 | Initiates | → Overweight | Get Alert |
| 05/28/2024 | Buy Now | -10.13% | RBC Capital | Brian Abrahams | $157 → $142 | Downgrade | Outperform → Sector Perform | Get Alert |
| 05/20/2024 | Buy Now | 5.06% | Needham | Gil Blum | → $166 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2024 | Buy Now | 13.29% | Mizuho | Uy Ear | $145 → $179 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 13.92% | Oppenheimer | Hartaj Singh | → $180 | Upgrade | Perform → Outperform | Get Alert |
| 05/03/2024 | Buy Now | 10.76% | JP Morgan | Anupam Rama | $177 → $175 | Maintains | Overweight | Get Alert |
| 05/02/2024 | Buy Now | 5.06% | Needham | Gil Blum | → $166 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | -18.99% | Cantor Fitzgerald | Kristen Kluska | → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 03/01/2024 | Buy Now | 5.7% | UBS | Colin Bristow | $164 → $167 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | -18.99% | Cantor Fitzgerald | Kristen Kluska | → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 02/29/2024 | Buy Now | -0.63% | RBC Capital | Brian Abrahams | $151 → $157 | Maintains | Outperform | Get Alert |
| 02/29/2024 | Buy Now | 8.86% | Citigroup | David Hoang | $160 → $172 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 17.09% | Barclays | Gena Wang | $141 → $185 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 5.06% | Needham | Gil Blum | $169 → $166 | Maintains | Buy | Get Alert |
| 02/20/2024 | Buy Now | -12.66% | Evercore ISI Group | Gavin Clark-Gartner | $108 → $138 | Maintains | In-Line | Get Alert |
| 02/20/2024 | Buy Now | 41.77% | Wedbush | Andreas Argyrides | → $224 | Reiterates | Outperform → Outperform | Get Alert |
| 02/16/2024 | Buy Now | 6.96% | Needham | Gil Blum | $140 → $169 | Maintains | Buy | Get Alert |
| 02/15/2024 | Buy Now | -18.99% | Cantor Fitzgerald | Kristen Kluska | → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 02/14/2024 | Buy Now | -8.23% | Mizuho | Uy Ear | $130 → $145 | Maintains | Buy | Get Alert |
| 02/14/2024 | Buy Now | -18.99% | Cantor Fitzgerald | Kristen Kluska | → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 01/31/2024 | Buy Now | 7.59% | BMO Capital | Kostas Biliouris | → $170 | Initiates | → Outperform | Get Alert |
| 01/30/2024 | Buy Now | 41.77% | Wedbush | Andreas Argyrides | → $224 | Reiterates | Outperform → Outperform | Get Alert |
| 01/29/2024 | Buy Now | -11.39% | Needham | Gil Blum | → $140 | Reiterates | Buy → Buy | Get Alert |
| 01/25/2024 | Buy Now | -4.43% | RBC Capital | Brian Abrahams | $155 → $151 | Maintains | Outperform | Get Alert |
| 01/10/2024 | Buy Now | -11.39% | Needham | Gil Blum | $93 → $140 | Maintains | Buy | Get Alert |
| 01/09/2024 | Buy Now | 41.77% | Wedbush | Andreas Argyrides | → $224 | Reiterates | Outperform → Outperform | Get Alert |
| 12/13/2023 | Buy Now | -28.48% | Citigroup | David Hoang | → $113 | Initiates | → Buy | Get Alert |
| 12/12/2023 | Buy Now | -31.01% | Deutsche Bank | Neena Bitritto-Garg | → $109 | Initiates | → Buy | Get Alert |
| 11/21/2023 | Buy Now | -6.33% | RBC Capital | Brian Abrahams | → $148 | Reiterates | Outperform → Outperform | Get Alert |
| 11/21/2023 | Buy Now | 41.77% | Wedbush | Andreas Argyrides | → $224 | Initiates | → Outperform | Get Alert |
| 11/02/2023 | Buy Now | -10.76% | Barclays | Gena Wang | $193 → $141 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | -49.37% | Cantor Fitzgerald | Kristen Kluska | $40 → $80 | Maintains | Neutral | Get Alert |
| 11/02/2023 | Buy Now | -41.14% | Needham | Gil Blum | $82 → $93 | Maintains | Buy | Get Alert |
| 10/31/2023 | Buy Now | -27.22% | JP Morgan | Anupam Rama | $211 → $115 | Maintains | Overweight | Get Alert |
| 10/31/2023 | Buy Now | -6.33% | RBC Capital | Brian Abrahams | $217 → $148 | Maintains | Outperform | Get Alert |
| 10/31/2023 | Buy Now | -74.68% | Cantor Fitzgerald | Kristen Kluska | $166 → $40 | Downgrade | Overweight → Neutral | Get Alert |
| 10/31/2023 | Buy Now | -7.59% | Morgan Stanley | Matthew Harrison | $183 → $146 | Maintains | Overweight | Get Alert |
| 10/31/2023 | Buy Now | -48.1% | Needham | Gil Blum | $185 → $82 | Maintains | Buy | Get Alert |
| 09/26/2023 | Buy Now | 1.27% | Mizuho | Uy Ear | → $160 | Reiterates | Buy → Buy | Get Alert |
| 08/03/2023 | Buy Now | 17.09% | Needham | Gil Blum | → $185 | Reiterates | → Buy | Get Alert |
| 08/03/2023 | Buy Now | 15.82% | Morgan Stanley | Matthew Harrison | $183 → $183 | Reiterates | Overweight → Overweight | Get Alert |
| 08/03/2023 | Buy Now | 41.14% | RBC Capital | Brian Abrahams | $221 → $223 | Maintains | Outperform | Get Alert |
| 07/14/2023 | Buy Now | 15.82% | Morgan Stanley | Matthew Harrison | $183 → $183 | Reiterates | Overweight → Overweight | Get Alert |
| 06/23/2023 | Buy Now | 1.9% | Citigroup | Neena Bitritto-Garg | $161 → $204 | Maintains | Buy | Get Alert |
| 06/23/2023 | Buy Now | 5.06% | Cantor Fitzgerald | Kristen Kluska | $153 → $166 | Maintains | Overweight | Get Alert |
| 06/23/2023 | Buy Now | 36.08% | Goldman Sachs | Salveen Richter | $188 → $215 | Maintains | Buy | Get Alert |
| 06/23/2023 | Buy Now | 34.81% | JP Morgan | Anupam Rama | $217 → $213 | Maintains | Overweight | Get Alert |
| 06/23/2023 | Buy Now | 15.82% | Morgan Stanley | Matthew Harrison | $183 → $183 | Reiterates | Overweight → Overweight | Get Alert |
| 06/23/2023 | Buy Now | 37.97% | RBC Capital | Brian Abrahams | → $218 | Reiterates | Outperform → Outperform | Get Alert |
| 06/23/2023 | Buy Now | -10.76% | Credit Suisse | Judah Frommer | → $141 | Reiterates | Neutral → Neutral | Get Alert |
| 06/23/2023 | Buy Now | -12.03% | Evercore ISI Group | Gavin Clark-Gartner | → $139 | Downgrade | Outperform → Neutral | Get Alert |
| 06/23/2023 | Buy Now | 17.09% | Needham | Gil Blum | → $185 | Reiterates | Buy → Buy | Get Alert |
| 06/16/2023 | Buy Now | 37.97% | RBC Capital | Brian Abrahams | → $218 | Reiterates | Outperform → Outperform | Get Alert |
| 06/06/2023 | Buy Now | 37.97% | RBC Capital | Brian Abrahams | → $218 | Reiterates | → Outperform | Get Alert |
| 05/30/2023 | Buy Now | -4.43% | Evercore ISI Group | Gavin Clark-Gartner | $173 → $151 | Maintains | Outperform | Get Alert |
| 05/26/2023 | Buy Now | 13.92% | Oppenheimer | Hartaj Singh | → $180 | Reiterates | Outperform → Outperform | Get Alert |
| 05/24/2023 | Buy Now | 17.09% | Needham | Gil Blum | → $185 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | 37.97% | RBC Capital | Brian Abrahams | $197 → $218 | Maintains | Outperform | Get Alert |
| 05/15/2023 | Buy Now | 9.49% | Evercore ISI Group | Gavin Clark-Gartner | $149 → $173 | Maintains | Outperform | Get Alert |
| 05/15/2023 | Buy Now | 11.39% | B of A Securities | Tazeen Ahmad | $164 → $176 | Maintains | Buy | Get Alert |
| 05/15/2023 | Buy Now | -4.43% | Credit Suisse | Judah Frommer | $138 → $151 | Maintains | Neutral | Get Alert |
| 05/15/2023 | Buy Now | 9.49% | UBS | Colin Bristow | $160 → $173 | Maintains | Buy | Get Alert |
| 05/15/2023 | Buy Now | 17.09% | Needham | Gil Blum | $160 → $185 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 3.8% | B of A Securities | Tazeen Ahmad | $164 → $164 | Maintains | Buy | Get Alert |
| 05/03/2023 | Buy Now | 24.68% | RBC Capital | Brian Abrahams | $200 → $197 | Maintains | Outperform | Get Alert |
| 05/03/2023 | Buy Now | -12.66% | Credit Suisse | Judah Frommer | $139 → $138 | Maintains | Neutral | Get Alert |
| 05/03/2023 | Buy Now | — | Cantor Fitzgerald | Kristen Kluska | $165 → $158 | Maintains | Overweight | Get Alert |
| 05/03/2023 | Buy Now | 1.27% | Needham | Gil Blum | → $160 | Reiterates | → Buy | Get Alert |
| 04/26/2023 | Buy Now | 17.09% | SMBC Nikko | David Hoang | → $185 | Initiates | → Outperform | Get Alert |
| 04/14/2023 | Buy Now | 3.8% | B of A Securities | Tazeen Ahmad | $164 → $164 | Maintains | Buy | Get Alert |
| 04/14/2023 | Buy Now | 1.27% | Mizuho | Uy Ear | → $160 | Reiterates | → Buy | Get Alert |
| 04/13/2023 | Buy Now | -5.7% | Evercore ISI Group | Gavin Clark-Gartner | → $149 | Maintains | Outperform | Get Alert |
| 04/04/2023 | Buy Now | 13.29% | Citigroup | Neena Bitritto-Garg | → $179 | Initiates | → Buy | Get Alert |
| 03/22/2023 | Buy Now | 10.76% | TD Cowen | Ritu Baral | $125 → $175 | Maintains | Outperform | Get Alert |
| 03/20/2023 | Buy Now | 3.8% | B of A Securities | Tazeen Ahmad | $164 → $164 | Maintains | Buy | Get Alert |
| 03/17/2023 | Buy Now | 3.8% | B of A Securities | Tazeen Ahmad | → $164 | Maintains | Buy | Get Alert |
| 03/17/2023 | Buy Now | -12.03% | Credit Suisse | Judah Frommer | $144 → $139 | Maintains | Neutral | Get Alert |
| 03/17/2023 | Buy Now | 1.27% | Mizuho | Uy Ear | → $160 | Reiterates | → Buy | Get Alert |
| 03/17/2023 | Buy Now | 26.58% | RBC Capital | Brian Abrahams | $226 → $200 | Maintains | Outperform | Get Alert |
| 03/17/2023 | Buy Now | 1.27% | Needham | Gil Blum | $200 → $160 | Maintains | Buy | Get Alert |
| 03/09/2023 | Buy Now | -5.06% | Oppenheimer | Hartaj Singh | $180 → $150 | Maintains | Outperform | Get Alert |
| 03/03/2023 | Buy Now | 30.38% | JP Morgan | Anupam Rama | $153 → $206 | Maintains | Overweight | Get Alert |
| 03/01/2023 | Buy Now | 8.23% | Evercore ISI Group | Gavin Clark-Gartner | $135 → $171 | Maintains | Outperform | Get Alert |
| 03/01/2023 | Buy Now | 43.04% | RBC Capital | Brian Abrahams | $195 → $226 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Sarepta Therapeutics (SRPT) stock?
The latest price target for Sarepta Therapeutics (NASDAQ:SRPT) was reported by Needham on June 27, 2024. The analyst firm set a price target for $235.00 expecting SRPT to rise to within 12 months (a possible 48.73% upside). 59 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sarepta Therapeutics (SRPT)?
The latest analyst rating for Sarepta Therapeutics (NASDAQ:SRPT) was provided by Needham, and Sarepta Therapeutics reiterated their buy rating.
When was the last upgrade for Sarepta Therapeutics (SRPT)?
The last upgrade for Sarepta Therapeutics Inc happened on May 14, 2024 when Oppenheimer raised their price target to $180. Oppenheimer previously had a perform for Sarepta Therapeutics Inc.
When was the last downgrade for Sarepta Therapeutics (SRPT)?
The last downgrade for Sarepta Therapeutics Inc happened on June 26, 2024 when Citigroup changed their price target from $172 to $176 for Sarepta Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Sarepta Therapeutics (SRPT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sarepta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sarepta Therapeutics was filed on June 27, 2024 so you should expect the next rating to be made available sometime around June 27, 2025.
Is the Analyst Rating Sarepta Therapeutics (SRPT) correct?
While ratings are subjective and will change, the latest Sarepta Therapeutics (SRPT) rating was a reiterated with a price target of $235.00 to $235.00. The current price Sarepta Therapeutics (SRPT) is trading at is $158.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.